We previously reported a 25% incidence of serious graftversus-host disease (GVHD) (that is, acute or chronic GVHD that caused death, lengthy hospitalization or disability, or resulted in recurrent major infections) among 171 hematopoietic cell transplantation (HCT) recipients after nonmyeloablative (NMA) regimen. Here we present a retrospective study applying the same criteria to 264 recipients of peripheral blood HCT after myeloablative (MA) regimen, and compare the results with the previous study after additional follow-up. The MA group was younger and had lower comorbidity scores at HCT than those in the NMA group. The overall incidence of serious GVHD was 17% (44/264) in the MA group versus 28% (48/171) in the NMA group. The adjusted hazard ratio (HR) of serious GVHD in the MA group compared to the NMA group was 0.65 (95% CI, 0.4-1.1); P ¼ 0.13, and if follow-up was censored at the onset of recurrent or progressive malignancy, HR was 0.67 (95% CI, 0.4-1.3), P ¼ 0.22. We conclude that the choice between MA and NMA regimens does not greatly affect the risk of serious GVHD as an overall indicator of outcomes related to either acute or chronic GVHD. Serious GVHD may be considered as an endpoint in clinical trials with GVHDrelated outcomes.
Introduction
In an effort to gain a more complete understanding of graft-versus-host disease (GVHD), and motivated by an interest in assessing the impact of either acute or chronic GVHD with the use of a single scale, we have explored alternative measurements that might be helpful in describing the overall GVHD-related outcome after allogeneic hematopoietic cell transplantation (HCT). As a first step toward this goal, we had earlier defined 'serious GVHD,' using criteria that summarize serious adverse effects related to acute or chronic GVHD. In particular, the criteria for 'serious GVHD' were intended to identify patients with severe repercussions related to 'extensive chronic GVHD,' since most patients with extensive chronic GVHD experience very little functional impairment, while others are disabled, have repeated infections or have lifethreatening complications.
At that time, we analyzed the incidence of serious GVHD among 171 consecutive patients who had HCT after nonmyeloablative (NMA) conditioning for treatment of hematological malignancies. 1 We reported a 25% incidence of serious GVHD among related and unrelated HCT recipients. Among the 171 patients, 7 had grade III acute GVHD and 84 had extensive chronic GVHD that did not meet the definition of serious GVHD. We concluded that the assessment of serious GVHD provided additional useful information in summarizing complications caused by donor cells, above and beyond the standard description of acute GVHD grades and classification of limited and extensive chronic GVHD.
In the present retrospective study, we analyze the incidence of serious GVHD as defined in our earlier work in a cohort of 264 related and unrelated HCT recipients who had myeloablative (MA) conditioning. We also compare these results with those described for recipients who received NMA conditioning, after updating their follow-up to a minimum of 800 days. 1 
Patients and methods

Serious GVHD (acute and chronic) definition
Concordant with our earlier work, 1 serious GVHD was diagnosed when a patient fulfilled one of the following criteria: (1) death related to GVHD or its treatment (that is, organ failure, infection or a fatal complication of treatment); (2) severe disability because of GVHD (for example, respiratory insufficiency or musculoskeletal contractures that severely affect activity of daily life); (3) three or more major infections in a single year during persistent GVHD (that is, sepsis, pneumonia, mold infection, central nervous system infection); (4) hospitalization for 460 days in a single year because of GVHD or (5) suicide or hospitalization for suicidal ideation because of GVHD or its treatment. The information was collected retrospectively by reviewing all available medical records, including those from the referring physician. Patients who died with infection and active leukemia during treatment for GVHD were not considered to have serious GVHD when other criteria for serious GVHD were absent. Two investigators independently reviewed the data to determine whether cases fulfilled criteria for serious GVHD as previously defined.
Patients
The study cohort included 264 consecutive HCT recipients who received hematopoietic growth factor-mobilized blood cell grafts from related or unrelated donors following an MA conditioning for treatment of hematological malignancies at our center. Included in the comparative analysis were the previously reported 171 patients who had a related or an unrelated HCT after NMA conditioning for treatment of hematological malignancies during the same period. , we updated follow-up in both cohorts for patients who had less than 800 days of follow-up, since results of the earlier study demonstrated that the onset of serious GVHD could occur as late as 800 days after HCT. From this review, we identified five additional patients in the NMA cohort who met the criteria for serious GVHD.
Techniques used for human leukocyte antigen (HLA) typing for unrelated transplant included molecular testing. Exons 2 and 3 of HLA-A, B and C alleles, and exon 2 of DRB1 and DQB1 alleles were typed by DNA sequencing methods or sequence-specific oligonucleotide hybridization in all donor-recipient pairs. Unrelated donors and recipients were defined as matched if they had identical probe hybridization patterns. The 82 DQB1*03 and 06-positive donor-recipient pairs with identical exon 2 oligonucleotide probe patterns potentially representing two different DQB1*0302, 0303, 0602 or 0603 alleles (one frequent allele and the other very rare) were considered to be matched.
Transplant protocols
Approximately half of the patients in the MA group received busulfan and cyclophosphamide (BUCY) 2 as the conditioning regimen (oral busulfan (BU) 4 mg/kg per day for 4 days, and intravenous cyclophosphamide (CY) 60 mg/kg per day for 2 days), and the other half received fractionated total-body irradiation (12 Gy) and CY at the same dose as for BUCY regimen. The conditioning regimens in the NMA group included 2 Gy total-body irradiation (TBI) on the day of transplantation (day 0) with 87 (33) 49 (29) High risk (HCT-CI ¼ 3 or more)
85 (32) 77 (46) Pre-transplant diagnosis, n (%) Chronic myeloid leukemia 37 (14) 16 (9 The combination of cyclosporine (CYA) and methotrexate was used for post-grafting immunosuppression in the MA group, with CYA administered for at least 180 days per protocol or longer, depending on the need for treatment of GVHD (see below). 3 The combination of CYA and mycophenolate mofetil was used for postgrafting immunosuppression for most patients in the NMA cohort. 4, 5 The minimal duration of CYA administration varied among NMA recipients with HLA-matched donors as time progressed and transplant protocols evolved. 6 Donor lymphocyte infusions (DLI) were administered to treat recurrent or progressive malignancy in both MA and NMA groups, and to treat low or declining donor chimerism in the NMA group. 7 Diagnosis and treatment of GVHD Diagnosis and grading of acute [8] [9] [10] and chronic 10-14 GVHD were done following established criteria. Treatment decisions were based on the attending physician's valuation of the severity of acute GVHD. The initial treatment was usually 1-2 mg/kg per day of prednisone for 10-14 days followed by tapering of steroid doses. Additionally, CYA and MMF administration was usually resumed at full doses in the NMA group. Extensive chronic GVHD was treated with prednisone at 1 mg/kg per day with twice daily CYA followed by a taper to alternate-day corticosteroids at 1 mg/kg. 15, 16 Steroid-refractory chronic GVHD 11,15 was treated with several strategies such as administration of mycophenolate mofetil, [17] [18] [19] tacrolimus, 20 sirolimus, 21 thalidomide, 22 psoralen and UVA, 23 and extracorporeal photopheresis. 24, 25 Treatment of chronic GVHD was continued for a minimum of 9 months, unless changes in therapy were clinically indicated. Supportive-care for patients with chronic GVHD was consistent with recently reported recommendations. 26 
Infections prophylaxis
The antibiotic prophylaxis regimens for the prevention of Pneumocystis pneumonia (PCP), bacterial, fungal and cytomegalovirus (CMV) infections used are described in previous publications. [27] [28] [29] Pre-emptive therapy for CMV infection and antibiotic prophylaxis against PCP, Haemophilus influenzae and Strptococcus pneumoniae infections were administered to patients with chronic GVHD that required systemic immunosuppression.
Statistics
The cumulative incidence of serious GVHD was estimated according to previously described methods. 30 Univariate proportional hazards models were used to evaluate risk factors for serious GVHD, treating deaths not related to GVHD as competing events. Risk factors that were tested in this analysis included patient's age, comorbidities as assessed by HCT-comorbidity index (HCT-CI), 31 donor type, donor-recipient gender pair, diagnosis at transplant, disease status (aggressive versus indolent), myeloid malignancies versus nonmyeloid malignancies, DLI before development of serious GVHD and number of cells infused per kilogram patient body weight (CD34, CD3 and total nucleated cells). All P-values were based on likelihood ratio statistics and were two sided. Overall survival was estimated according to the Kaplan-Meier method.
Results
Patients in the MA cohort were younger and had lower comorbidity scores at transplant than those in the NMA group (Table 1) . The proportion of patients with myeloid disease was 74% (195/264) in the MA cohort, compared to 33% (57/171) in the NMA group. All patients undergoing transplant for Hodgkin's lymphoma or multiple myeloma were in the NMA cohort. Fifty-two percent of the patients in the MA cohort had aggressive disease at transplant (chronic myeloid leukemia in blast crisis, any lymphoid or myeloid acute leukemia, refractory anemia with excess blast in transformation myelodysplastic syndrome, large cell lymphoma and plasma cell leukemia), compared to 27% in the NMA group. The percentages of patients with disease in remission at transplant were 57 and 22% in the MA and NMA cohorts, respectively. The proportions of patients with HLA-matched related donors were similar in the two groups. Twenty-eight patients (11%) in the MA cohort had HLA-mismatched unrelated donors, compared to none in the NMA group. Donor-recipient gender pairs, the number of cells contained in the graft per kilogram of patient weight, and the proportions of patients who received DLI were similarly distributed between the two groups.
The minimal duration of CYA administration was shorter among most patients who had NMA conditioning, compared to those who had MA conditioning, as previously reported. 6 The actual duration of immunosuppression depended on the occurrence of acute or chronic GVHD. With either type of conditioning regimen, most patients with serious GVHD had continuous treatment with immunosuppressive medications after HCT.
There were no statistically significant differences in the incidence of grades III-IV acute GVHD or extensive chronic GVHD between the two groups ( Table 2 ). The cumulative incidence of nonrelapse mortality (NRM) at 2 year was 27% in the MA cohort and 25% in the NMA cohort.
The overall incidence of serious GVHD was 17% (44/264) among MA patients, with a median follow-up of surviving patients of 50 (range, 26-84) months, compared to 28% (48/171) for NMA patients, with a median follow-up of 38 (range, 26-77) months. The onset of serious GVHD occurred at a median of 6.2 (range, 0.8-66.7) months in the MA group compared to 6.8 (range, 1.9-44.7) months after transplant in the NMA cohort. In the univariate analysis, the hazard ratio (HR) for serious GVHD for the MA cohort compared to the NMA group was 0.58 (95% CI, 0.4-0.9; P ¼ 0.008; Figure 1a) . Adjusting for patient age, HCT-CI, aggressive versus indolent malignancy at transplant, remission versus relapse at transplant, myeloid versus nonmyeloid malignancy, patient and donor gender, donor type, HLA-mismatch and prior DLI attenuated the association of the conditioning type with the risk of serious GVHD, such that the difference was not statistically significant (HR ¼ 0.65; 95% CI, 0.4-1.1; P ¼ 0.13). The strongest risk factor for serious GVHD was higher HCT-CI (Po0.0001).
After censoring follow-up for patients with recurrent or progressive malignancy in order to control for the effect of post-relapse medical interventions, the cumulative incidence of serious GVHD at 4 years was 14% for the MA group and 21% for the NMA group, and the adjusted HR for serious GVHD in the MA cohort versus the NMA cohort was 0.67 (95% CI, 0.4-1.3; P ¼ 0.22; Figure 1b) . Table 2 displays the overall incidence of acute, chronic and serious GVHD between the MA and NMA groups. Among the 264 MA patients, 28 (11%) had grade III acute GVHD that did not meet the criteria for serious GVHD compared to 6 (4%) among the 171 NM patients. Among the MA patients, 147 (56%) had extensive chronic GVHD that did not meet the criteria for serious GVHD compared to 80 (47%) patients in the NMA group. Among the 44 MA patients with serious GVHD, 43% fulfilled the serious GVHD criteria for acute GVHD and 57% for chronic GVHD compared to 28 and 71%, respectively, for the 48 patients with serious GVHD in the NMA group.
Reasons for serious GVHD were similar in the MA and NMA cohorts (Table 3) . Death related to GVHD was the most common reason for classification of serious GVHD in both groups.
Discussion
The outcome after allogeneic HCT for the treatment of hematological malignancies depends on graft-versus-leukemia (GVL) effects and on acute and chronic GVHD-related damage, both mediated by donor cells that respond to alloantigens in the recipient. [32] [33] [34] The lower risk of recurrent malignancy associated with GVHD does not always translate into a survival advantage or improved quality of life, because patients with GVHD are at risk for complications related to GVHD-mediated tissue damage and immunosuppressive treatments. 35, 36 In fact, GVHD continues to be a leading cause of NRM after HCT with either MA or NMA conditioning regimens. 37 The categorization of acute and chronic GVHD according to 'day 100 post-transplant,' and the limitation in the reproducibility of the traditional classification of chronic GVHD (that is, limited and extensive), potentially 
Table 3
Reasons for serious graft-versus-host disease (GVHD) after hematopoietic cell transplant, according to myeloablative (MA) and nonmyeloablative (NMA) conditioning regimens (17) 25 (17) Serious GVHD 44 (17) 48 (28) a Only patients at risk.
Serious GVHD after hematopoietic stem cell transplantation O Sala-Torra et al affects the reporting of acute and chronic GVHD outcomes after transplant. Well-established grading criteria have long been used to assess the severity of acute GVHD. No comparable validated criteria have been established to assess the severity of 'extensive chronic GVHD,' although consensus criteria have been proposed recently. 38 As a first step in exploring ways to add more value in assessing outcomes of both acute and chronic GVHD, we defined serious GVHD as the severe manifestations of GVHD in which the negative consequences overwhelm the benefits of any graft-versus-tumor effect on the incidence of relapse. We based this definition on the classic definition of serious adverse events: death or a threat to life, prolonged hospitalization or disability. Because of the impact of acute GVHD in the development of chronic GVHD, and the negative impact of increased chronic GVHD severity on clinical outcome, we considered assessing serious GVHD according to unified criteria for both acute and chronic GVHD.
In the current retrospective study, results of the univariate analysis revealed a lower overall incidence of serious GVHD for patients in the MA group compared to the NMA group, but after adjustment in the multivariate model, the difference was no longer statistically significant. In our study, patients in the MA group had lower HCT-CI than those in the NMA group. We have previously reported that HCT-CI is a predictor for NRM after MA and NMA conditioning regimens. 31, 39 HCT-CI is also a predictor for grades III-IV acute GVHD after MA conditioning. 40 In the current study, death was the most common reason for serious GVHD in both groups. We speculate that the association of NRM with higher HCT-CI scores may be explained in part by the development of serious GVHD. 31, 39 Because the NMA cohort was older and had higher HCT-CI than those in the MA group, one might have expected a higher incidence of serious GVHD in the NMA than in MA group, because patients with severe comorbidity and impaired organ reserve in the lungs, liver, kidneys or heart are likely to be less able to tolerate severe GVHD and the toxicity of immunosuppressive treatment. Nonetheless, in the current study, the incidence of serious GVHD before relapse or progression of hematological malignancy was similar (14 versus 21%) after MA and NMA conditioning regimens, respectively.
In previous studies, NMA conditioning was associated with a lower incidence of grades III-IV acute GVHD compared to MA conditioning, but rates of chronic extensive GVHD were similar in the two groups. [41] [42] [43] In the current study, however, the overall incidence of grades III-IV acute GVHD was similar in the two groups. Considering the older age and the higher HCT-CI scores in the NMA population compared to the MA cohort, the incidence of grades III-IV acute GVHD in the NMA cohort is lower than one might have been expected. The overall incidence of chronic extensive GVHD was similar in the two groups.
Demographic differences between the MA and NMA patient cohorts could not be avoided, since NMA conditioning regimens were used preferentially for older patients and for those with comorbidity that precluded the use of MA conditioning regimens. Since a matched cohort analysis was not feasible, we attempted to control for demographic differences between the two cohorts by using multivariate regression analysis. Our conclusion that the use of MA or NMA conditioning regimens does not greatly affect the incidence of serious GVHD requires further confirmation in retrospective or prospective studies with a better balance of demographic characteristics in the two groups.
The results of this study reinforce the conclusions of our previous analysis that assessment of serious GVHD provides useful information regarding GVHD-related outcome, as it singles out those patients whose acute and chronic GVHD caused NRM or severe impairment. We acknowledge that the criteria for serious GVHD need improvement. The purpose of defining serious GVHD was to describe a category of GVHD that was (a) medically unacceptable, (b) applicable both to acute and chronic GVHD and (c) applicable for both retrospective and prospective studies. We encountered several limitations when we applied this definition. First, laborious chart maintenance and review was necessary in order to determine whether GVHD was serious or not. Second, some criteria, such as the 60-day threshold for the duration of hospitalization because of GVHD, have arbitrary boundaries. Third, some elements, such as disability, remain difficult to define.
We recognize the difficulty of reaching a consensus among professionals in defining conditions where burdens are judged to outweigh benefits. Nonetheless, we believe that we have used consistent criteria in comparing results of HCT with MA versus NMA conditioning in this study, which supports the validity of our conclusion that the choice between MA and NMA conditioning regimens does not greatly affect the risk of serious GVHD. Serious GVHD criteria could be used as an end point of clinical trials designed to improve GVHD-related outcomes. Nevertheless, development of a more easily applied definition would be helpful in the overall assessment of acute and chronic GVHD-related outcomes after HCT. In future studies, for example, criteria for grades III-IV acute GVHD could be combined with criteria for overall grades 2-3 chronic GVHD as defined recently by the NIH Consensus Development Project 38 as an overall indicator of clinical outcomes related to either acute or chronic GVHD.
